NEW YORK, June 15 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and other major health threats, announced today that a sponsored laboratory study agreement has been executed with The University of Texas M. D. Anderson Cancer Center to support development of the Company's Degrasyn class of cancer-fighting compounds.
